Cargando…
Lung Cancer Mortality in the Lung Screening Study Feasibility Trial
The Lung Screening Study was a multicenter controlled feasibility trial that randomly assigned subjects to undergo two rounds of screening with either low-dose spiral computed tomography (LDCT) or chest X-ray (CXR). Long-term follow-up was performed to evaluate any differences in lung-cancer-specifi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649695/ https://www.ncbi.nlm.nih.gov/pubmed/31360863 http://dx.doi.org/10.1093/jncics/pky042 |
_version_ | 1783438036376223744 |
---|---|
author | Doroudi, Maryam Pinsky, Paul F Marcus, Pamela M |
author_facet | Doroudi, Maryam Pinsky, Paul F Marcus, Pamela M |
author_sort | Doroudi, Maryam |
collection | PubMed |
description | The Lung Screening Study was a multicenter controlled feasibility trial that randomly assigned subjects to undergo two rounds of screening with either low-dose spiral computed tomography (LDCT) or chest X-ray (CXR). Long-term follow-up was performed to evaluate any differences in lung-cancer-specific and all-cause mortality between arms. In 2000, subjects were randomly assigned at six screening centers. Linkage with the National Death Index was performed to ascertain long-term mortality for subjects. Median follow-up for mortality of the 1660 and 1658 subjects randomly assigned to LDCT and CXR, respectively, was 5.2 years. There were 32 and 26 deaths from lung cancer in the two groups, respectively, corresponding to lung cancer death rates of 3.84 and 3.10 per 1000 person-years, and a risk ratio of 1.24 (95% confidence interval = 0.74 to 2.08). The risk ratio for all-cause mortality was 1.20 (95% confidence interval = 0.94 to 1.54). These findings can contribute to the overall knowledge on LDCT lung cancer screening. |
format | Online Article Text |
id | pubmed-6649695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-66496952019-07-29 Lung Cancer Mortality in the Lung Screening Study Feasibility Trial Doroudi, Maryam Pinsky, Paul F Marcus, Pamela M JNCI Cancer Spectr Brief Communication The Lung Screening Study was a multicenter controlled feasibility trial that randomly assigned subjects to undergo two rounds of screening with either low-dose spiral computed tomography (LDCT) or chest X-ray (CXR). Long-term follow-up was performed to evaluate any differences in lung-cancer-specific and all-cause mortality between arms. In 2000, subjects were randomly assigned at six screening centers. Linkage with the National Death Index was performed to ascertain long-term mortality for subjects. Median follow-up for mortality of the 1660 and 1658 subjects randomly assigned to LDCT and CXR, respectively, was 5.2 years. There were 32 and 26 deaths from lung cancer in the two groups, respectively, corresponding to lung cancer death rates of 3.84 and 3.10 per 1000 person-years, and a risk ratio of 1.24 (95% confidence interval = 0.74 to 2.08). The risk ratio for all-cause mortality was 1.20 (95% confidence interval = 0.94 to 1.54). These findings can contribute to the overall knowledge on LDCT lung cancer screening. Oxford University Press 2018-09-18 /pmc/articles/PMC6649695/ /pubmed/31360863 http://dx.doi.org/10.1093/jncics/pky042 Text en © The Author(s) 2018. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contactjournals.permissions@oup.com |
spellingShingle | Brief Communication Doroudi, Maryam Pinsky, Paul F Marcus, Pamela M Lung Cancer Mortality in the Lung Screening Study Feasibility Trial |
title | Lung Cancer Mortality in the Lung Screening Study Feasibility Trial |
title_full | Lung Cancer Mortality in the Lung Screening Study Feasibility Trial |
title_fullStr | Lung Cancer Mortality in the Lung Screening Study Feasibility Trial |
title_full_unstemmed | Lung Cancer Mortality in the Lung Screening Study Feasibility Trial |
title_short | Lung Cancer Mortality in the Lung Screening Study Feasibility Trial |
title_sort | lung cancer mortality in the lung screening study feasibility trial |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649695/ https://www.ncbi.nlm.nih.gov/pubmed/31360863 http://dx.doi.org/10.1093/jncics/pky042 |
work_keys_str_mv | AT doroudimaryam lungcancermortalityinthelungscreeningstudyfeasibilitytrial AT pinskypaulf lungcancermortalityinthelungscreeningstudyfeasibilitytrial AT marcuspamelam lungcancermortalityinthelungscreeningstudyfeasibilitytrial |